PeterDGorevicMD

PubMed

• Amyopathic dermatomyositis may be on the spectrum of autoinflammatory disease: A clinical review.
  Saika Sharmeen, Lisa Christopher-Stine, Joann N Salvemini, Peter Gorevic, Richard Clark, Qingping Yao> ;Rheumatology and Immunology Research. 2024 Mar 1
• Genetically transitional disease: conceptual understanding and applicability to rheumatic disease.
  Timothy B Niewold, Ivona Aksentijevich, Peter D Gorevic, Greg Gibson, Qingping Yao> ;Nature Reviews. Rheumatology. 2024 Feb 28
• 3 citations
  Cardiac Amyloidosis.
  Michelle Weisfelner Bloom, Peter D Gorevic> ;Annals of Internal Medicine. 2023 Mar 1
• 5 citations
  A novel nucleotide-binding oligomerization domain 2 genetic marker for Yao syndrome.
  Brianne Navetta-Modrov, Hafsa Nomani, Mark Yun, Jie Yang, Joann Salvemini, Olga Aroniadis, Richard Clark, Peter D Gorevic, Qingping Yao> ;Journal of the American Academy of Dermatology. 2023 Jul 1
• Genetic variations in NLRP3 and NLRP12 genes in adult-onset patients with autoinflammatory diseases: a comparative study.
  Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Yao, Q. P., Mark Yun, Zuoming Deng,...> ;Frontiers in Immunology. 2023 Jan 1
• 2 citations
  Implications of combinedand other gene mutations in autoinflammatory diseases.
  Hafsa Nomani, Zuoming Deng, Brianne Navetta-Modrov, Jie Yang, Mark Yun, Olga Aroniadis, Peter Gorevic, Ivona Aksentijevich, Qingping Yao> ;Frontiers in Immunology. 2023 Jan 1
• 11 citations
  Genetically transitional disease: a new concept in genomic medicine.
  Qingping Yao, Peter Gorevic, Bo Shen, Greg Gibson> ;Trends in Genetics. 2023 Feb 1
• 10 citations
  Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
  Thomas H Brannagan, Teresa Coelho, Annabel K Wang, Michael J Polydefkis, Peter J Dyck, John L Berk, Brian Drachman, Peter Gorevic, Carol Whelan, Isabel Conceição, Viol...> ;Journal of Neurology. 2022 Dec 1
• 1 citations
  NOD2 Versus MEFV: Differential Diagnosis of Yao Syndrome and Familial Mediterranean Fever.
  Qingping Yao, Min Shen, Peter Gorevic> ;Rheumatology and Immunology Research. 2021 Dec 1
• 1 citations
  The enigma of complement activation in mixed cryoglobulinemia.
  Peter D. Gorevic, Berhane Ghebrehiwet> ;Digestive and Liver Disease. 2021 May 26
• 11 citations
  Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
  Peter D. Gorevic, Jaclyn Franklin, Jihong Chen, Gautam Sajeev, Jessie Wang, Hollis Lin> ;Expert Opinion on Pharmacotherapy. 2021 Jan 2
• 71 citations
  Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
  David Adams, Michael Polydefkis, Alejandra González-Duarte, Jonas Wixner, Arnt V. Kristen, Hartmut Schmidt, John L. Berk, Inés Asunción Losada López, Angela Dispenzier...> ;The Lancet. Neurology. 2021 Jan 1
• 42 citations
  Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NE...
  Thomas H. Brannagan, A. K. Wang, T. Coelho, M. Waddington Cruz, Michael Polydefkis, Peter J. Dyck, V. Plante-Bordeneuve, John L. Berk, Fabio Barroso, Giampaolo Merlini...> ;European Journal of Neurology. 2020 Aug 1
• 41 citations
  Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
  Laura Obici, John L. Berk, Alejandra González-Duarte, Teresa Coelho, Julian D. Gillmore, Hartmut Schmidt, Matthias Schilling, Taro Yamashita, Céline Labeyrie, Thomas H...> ;Amyloid. 2020 Mar 4
• 138 citations
  Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
  Arnt V. Kristen, Senda Ajroud-Driss, Isabel Conceição, Peter D. Gorevic, Theodoros Kyriakides, Laura Obici> ;Neurodegenerative Disease Management. 2019 Feb 1
• 632 citations
  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
  Merrill D. Benson, Márcia Waddington-Cruz, John L. Berk, Michael Polydefkis, Peter J. Dyck, Annabel K. Wang, Violaine Planté-Bordeneuve, Fabio Barroso, Giampaolo Merli...> ;The New England Journal of Medicine. 2018 Jul 5
• 19 citations
  The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia.
  Ahmed El-Shamy, Andrea D. Branch, Thomas D. Schiano, Peter D. Gorevic> ;Frontiers in Immunology. 2018 May 29
• 39 citations
  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.
  Peter J. Dyck, John C. Kincaid, P. James B. Dyck, Vinay Chaudhry, Namita Goyal, Christina Alves, Hayet Salhi, Janice F. Wiesman, Céline Labeyrie, Jessica Robinson-Papp...> ;Muscle & Nerve. 2017 Nov 1
• 6 citations
  Cutaneous Manifestations of Familial Transthyretin Amyloid Polyneuropathy
  Julien Lanoue, Nancy Wei, Peter D. Gorevic, Robert G. Phelps> ;The American Journal of Dermatopathology. 2016 Oct 1
• 470 citations
  Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
  John L. Berk, Ole B. Suhr, Laura Obici, Yoshiki Sekijima, Steven R. Zeldenrust, Taro Yamashita, Michael A. Heneghan, Peter D. Gorevic, William J. Litchy, Janice F. Wie...> ;JAMA. 2013 Dec 25
• 16 citations
  Amyloid and inflammation
  Peter D. Gorevic> ;Proceedings of the National Academy of Sciences of the United States of America. 2013 Oct 8
• 5 citations
  Rituximab in refractory and relapsed dermatomyositis and polymyositis: comment on the article by Oddis et al.
  Janet Cuttner, Harry Spiera, Peter D. Gorevic> ;Arthritis and Rheumatism. 2013 Sep 1
• 34 citations
  AA Amyloidosis: Mount Sinai Experience, 1997–2012
  Daniel Bunker, Peter D. Gorevic> ;The Mount Sinai Journal of Medicine, New York. 2012 Nov 1
• 33 citations
  Rheumatoid Factor, Complement, and Mixed Cryoglobulinemia
  Peter D. Gorevic> ;Clinical & Developmental Immunology. 2012 Aug 26
• 35 citations
  The diflunisal trial : study accrual and drug tolerance
  John L. Berk, Ole B. Suhr, Yoshiki Sekijima, Taro Yamashita, Michael A. Heneghan, Steven R. Zeldenrust, Yukio Ando, Shu-ichi Ikeda, Peter D. Gorevic, Giampaolo Merlini...> ;Amyloid. 2012 May 24
• Join now to see all

Journal Articles

• Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis  
  William J Litchy, Peter D Gorevic, Morie A Gertz, Amil M Shah, John L Berk, Peter J Dyck, The New England Journal of Medicine

Other

• Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases 
  Gorevic PD
  http://www.uptodate.com/contents/causes-and-diagnosis-of-secondary-aa-amyloidosis-and-relation-to-rh
  UpToDate, Wolters Kluwer Health - 2012-08-29
• Genetic factors in the amyloid diseases 
  Gorevic PD
  http://www.uptodate.com/contents/genetic-factors-in-the-amyloid-diseases
  UpToDate, Wolters Kluwer Health - 2012-07-13
• Musculoskeletal manifestations of amyloidosis 
  Gorevic PD
  http://www.uptodate.com/contents/musculoskeletal-manifestations-of-amyloidosis
  UpToDate, Wolters Kluwer Health - 2012-04-19
• Pathogenesis of secondary (AA) amyloidosis 
  Gorevic PD
  http://www.uptodate.com/contents/pathogenesis-of-secondary-aa-amyloidosis
  UpToDate, Wolters Kluwer Health - 2012-06-26
• An overview of amyloidosis 
  Gorevic PD
  http://www.uptodate.com/contents/an-overview-of-amyloidosis
  UpToDate, Wolters Kluwer Health - 2012-09-13
• Treatment of secondary (AA) amyloidosis 
  Gorevic PD
  http://www.uptodate.com/contents/treatment-of-secondary-aa-amyloidosis
  UpToDate, Wolters Kluwer Health - 2012-07-17
• Join now to see all